Global Health & Biotech Archives | Page 25 of 287 | Be Korea-savvy

Archive by category Global Health & Biotech

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

TEL AVIV, Israel, May 19, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical [...]

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

  May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real time Catheter offers enhanced procedural guidance without the need for general [...]

Magstim Granted EU MDR Certification

Magstim Granted EU MDR Certification

Magstim Passes Compliance with Strict European Union Medical Device Regulations Expanding Magstim Access to Entire EU Marketplace WHITLAND, United Kingdom, May 16, 2025 (Korea Bizwire) – Magstim has been granted EU MDR Certification for all transcranial magnetic stimulation (TMS) systems, demonstrating compliance with strict European Union Medical Device Regulations. This provides a path for Magstim [...]

Moody’s Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Moody’s Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

TEL AVIV, Israel, May 15, 2025 (Korea Bizwire) – Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody’s Investor Services (“Moody’s”) has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization [...]

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects

May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net [...]

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (Korea Bizwire) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings [...]

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now

May 15, 2025 AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impact Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has released its 10th annual Future Health Index (FHI) report, highlighting the growing strain [...]

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure [...]

Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award

Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award

WASHINGTON, May 13, 2025 (Korea Bizwire) – The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal vaccine and leadership in global vaccine research and access, and its Rising Star Award to dedicated physician and public health specialist Livancliff Mbianke, MD, [...]

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. (Image courtesy of Teva Pharmaceutical Industries Ltd.) The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse [...]